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Two researchers from the University of
Dundee, Scotland - Grahame Hardie
and Dario Alessi - have jointly solved a
mystery that each had been puzzling
over for several years (see ‘The bottom
line’ box for a summary of their work).
Hardie had been looking for the
upstream kinase that regulates the
metabolic regulator AMP-activated
kinase (AMPK) (see the ‘Background’
box), while only a short walk away Alessi
had been searching for the downstream
target of the tumor suppressor and
protein kinase LKB1. Like fitting two
halves of a jigsaw together, the two
researchers soon realized that each held
the solution to the other’s problem.
Hardie has studied AMPK for well
over a decade. He knew that it was
switched on in situations of metabolic
stress, such as low glucose or hypoxia,
and by exercise in muscle, and that this
required it to be phosphorylated by an
upstream kinase. His team had tried
purifying this upstream kinase activity
and had attempted to determine the
amino-acid sequence associated with
the activity. But the upstream kinase is
not an abundant protein and their
approach was not proving successful.
In an attempt to speed things up,
Hardie’s group switched from human
cells to brewers’ yeast (Saccharomyces
cerevisiae), an organism known to have
a homologous kinase to AMPK called
Snf1. With the help of two collabora-
tors, Mike Stark in Dundee and Martin
Schmidt in Pittsburgh, they could
‘mine’ the yeast genome sequence,
which had been completed several
years earlier, and use sophisticated
analysis tools that are not yet as reli-
able for more complex mammalian
systems. With this approach they
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The bottom line  
• AMP-activated protein kinase (AMPK) is activated in response to cellu-
lar stresses that deplete ATP, but its upstream activator kinase has
proved difficult to purify and characterize.
• Searching for the upstream kinase(s) that regulate(s) the AMPK
homolog Snf1 led to the discovery of Elm1 in yeast, and sequence
comparisons revealed Elm1 to be a close relative of LKB1, a tumor
suppressor gene product and protein kinase.
• Studies of LKB1 had shown its involvement in the cancer-prone Peutz-
Jeghers syndrome, but its downstream mode of action was unknown.
• LKB1 has now been identified as the upstream regulator of AMPK,
placing LKB1 - together with its binding partners STRAD and MO25 -
in the middle of a crucial biochemical cascade that regulates cellular
metabolism.
• This finding links the pathways controlling cellular metabolism and cell
proliferation, and makes LKB1 an attractive potential therapeutic
target for a wide range of clinical disorders.identified Elm1, Pak1 and Tos3, three
kinases that act upstream of Snf1 [1].
Hardie then returned to the human
genome and searched for homologs of
the three yeast kinases. The best match
was a serine threonine kinase, STK11.
“I’d never heard of it - it meant nothing
to me,” says Hardie. “But to my great
surprise, when I looked it up on
MEDLINE it turned out to be another
name for LKB1, and I knew about
LKB1 because Dario Alessi had been
working on it, and he was just up
the corridor.”
For four years Alessi had been study-
ing LKB1, and searching for its function.
It had all the hallmarks of an important
protein. Since its gene was sequenced in
1998, researchers had found 100 differ-
ent mutations of this protein, all of
which came from patients with Peutz-
Jeghers syndrome, a genetic condition
that puts people at risk of developing
multiple benign tumors in the intestine
as well as more aggressive forms of
cancer. All the evidence suggested that
LKB1 played a critical role in regulating
cell proliferation.
“This wasn’t the first time that
Grahame Hardie and I had discussed a
possible connection between LKB1
and AMPK,” recounts Alessi. “Two
years earlier we had thought about it
and, although it was a very long shot at
the time, had attempted a couple of
experiments to see if my preparation of
LKB1 would activate AMPK.” But the
experiments showed no sign of success
and the idea was rapidly forgotten.
Anyway, the coincidence that two
people working in adjacent labs might
be studying two protein kinases that
also happened to be adjacent to each
other in a biological pathway seemed
too good to be true.
But this year, things were different.
In the intervening time, Alessi’s team
(in collaboration with Hans Clevers’
group in The Netherlands) had char-
acterized LKB1 more closely and
found that it was only active when
joined to two subunits, Ste20-related
adaptor protein (STRAD) and mouse
protein 25 (MO25). The earlier activa-
tion attempts had been carried out
using LKB1 alone. Hardie visited
Alessi’s lab late one afternoon, and by
lunchtime the next day they had
results from the first experiment. “We
had hit the jackpot,” claims Alessi,
and the results are published in this
issue of Journal of Biology [2].
Working together, they had com-
bined the Alessi lab’s human LKB1 and
its subunits - which were expressed in
cultures of human kidney cells (known
as 293 cells, which readily take up
DNA) - with AMPK that Hardie’s group
had made by expression of the rat
protein in bacteria. In this reconstituted
cell-free system they found that LKB1
massively activated AMPK. “The great
thing was that because Dario had been
working on LKB1 for three or four years,
although without knowing what lay
immediately downstream of it, we were
able to make progress very quickly. He
had all the right reagents and tools
available to test our ideas,” explains
Hardie. Suddenly two areas of work
joined together to form a whole that
was much greater than the sum of its
parts (see the ‘Behind the scenes’ box
for more on the future of the work).
Some years earlier, Hardie’s group
had shown that AMPK needed to be
phosphorylated by an upstream kinase
at a site (Thr172) in the ‘activation
loop’ of the kinase domain. It was also
known that, when activated, AMPK
had a negative influence on cell
growth, and that AMPK is activated by
various kinds of stress, particularly
stresses that cause depletion of ATP. “It
switches off any non-essential
processes in the cell, one of which
would be cell division,” says Hardie.
“If you are short of ATP you want to
concentrate on surviving; you don’t
want to think about dividing.”
On the other hand, LKB1 was
known to be mutated in cells from
patients with Peutz-Jegher’s syndrome,
and now there was the intriguing pos-
sibility that their disabled LKB1 leaves
AMPK unable to perform its regulatory
role, allowing cell proliferation to carry
on unchecked. “This is a very impor-
tant finding because it brings two
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Background
• AMP-activated protein kinase (AMPK) is triggered in response
to various forms of metabolic stress (such as exercise in muscle)
that alter the relative concentrations of AMP and ATP within the cell.
• Having been activated by low ATP/high AMP, AMPK switches on cata-
bolic pathways that generate ATP (such as glucose uptake and oxida-
tion), while inhibiting ATP-consuming processes, such as biosynthesis
and cell proliferation. AMPK thus plays a key role in regulating lipid
and glucose metabolism and has been implicated in diabetes, obesity
and cardiac diseases.
• Like many protein kinases, AMPK acts within a signaling cascade and is
activated when it is phosphorylated by an upstream kinase.
• Peutz-Jeghers syndrome is a genetic condition that causes benign
tumors and also puts people at greatly increased risk of developing
more aggressive forms of cancer. LKB1, a protein kinase, is the
product of the tumor suppressor gene LKB1 which is mutated in
cells from patients with Peutz-Jeghers syndrome. 
Journal of Biology 2003, 2:24universes together, the small but
important world of LKB1 and the well-
researched world of AMPK,” com-
ments Jim Woodgett from Ontario
Cancer Institute, in Toronto, Canada.
“This is a new interface and in science,
interfaces between areas are often
scenes of rapid progress.”
“It is a link between metabolism
and cell proliferation, which is part of
an emerging theme,” agrees Tony
Pawson, who works at the Samuel
Lunenfeld Research Institute in
Toronto. “In the rush of excitement
with signal transduction over the past
couple of decades there has been a ten-
dency to think of metabolism as
somehow boring, but it is now coming
back with a vengeance, and it is excit-
ing to see metabolism tie in so nicely
to signal transduction.”
Verification
More work was clearly needed to estab-
lish whether the early results were an
artifact observed only in a reconsti-
tuted cell-free system, or whether the
finding would also hold in living cells.
The first step was to look at LKB1 and
AMPK in HeLa cells. Alessi and his
team already knew that LKB1 is not
expressed in these highly abnormal
transformed human cancer cells, and
Hardie’s team had previously discov-
ered that HeLa cells produced AMPK,
but that the kinase was not activated
by treatments that usually activate
AMPK. The answer seemed obvious -
the lack of LKB1 explained the lack of
activation of AMPK.
What’s more, Alessi and colleagues
had already introduced genes into a
line of HeLa cells that restored their
ability to produce LKB1. Now Hardie
tested these cells and found that AMPK
was indeed activated in them. It was
the first evidence that LKB1 could acti-
vate AMPK in intact cells. “When we
initially tried to publish this work,
however, the reviewers expressed
caution,” notes Hardie. The issue was
so big that they asked for a greater
burden of proof. The problem was that
HeLa cells, which are derived from a
woman who died of cancer many years
ago, have many other mutations as
well as lacking LKB1. “The evidence
showed that LKB1 was sufficient to
activate AMPK, but because we could
not rule out the possibility that other
upstream kinases might also be missing
in HeLa cells, we could not say that
LKB1 was necessary,” explains Hardie.
As a consequence, Hardie and
Alessi approached Tomi Mäkelä at the
University of Helsinki, Finland, who
was growing immortalized mouse
embryo fibroblasts in which the LKB1
gene had been knocked out. “We were
very fortunate that the Finnish group
agreed to give us the cells so quickly,”
says Hardie. Soon, the Hardie and
Alessi labs showed that AMPK was acti-
vated normally in wild-type mouse
embryo fibroblasts, but in the cells
from the LKB1 knockout embryos it
was not activated. This time the evi-
dence seemed compelling. “Now LKB1
was both sufficient and necessary,”
comments Hardie. “LKB1 is the
upstream kinase in these cells,
although we can’t say that this is true
in all cell types. There could be other
upstream kinases in tissues like
muscle, or elsewhere, but at least in
mouse embryo fibroblasts LKB1 seems
to account for all of the upstream
kinase activity acting on AMPK.”
The work also leaves open the pos-
sibility that LKB1 may influence many
other downstream targets. “There are
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Behind the scenes
Journal of Biology asked Dario Alessi and Grahame Hardie about the moti-
vation for, and future of, their experiments linking LKB1 and AMPK.
What motivated this work?
“Both groups of researchers were driven by the desire to understand the
control of metabolism and cell growth, and to see how this could relate to
clinical diseases ranging from diabetes to cancer,” agree Alessi and Hardie. 
How long did the experiments take?
“I had been working on LKB1 for four years,” says Alessi, while Hardie
notes that he had been studying AMPK “for over a decade. Once the link
was made, however, the work described in the current paper took a few
weeks.”
What are the next steps and what does the future hold? 
“There are numerous questions to be answered,” says Hardie. “For
example, we currently know of 14 other human protein kinases that are
closely related to AMPK but have no known functions. The question now
is whether LKB1 activates these as well. If so, the tumor suppressor activ-
ity of LKB1 might be mediated through one of these as well as, or instead
of, through AMPK. There is also a pressing need to discover the mecha-
nism that enables phenformin to stimulate AMPK via LKB1. This might be
the key to development of a second generation of phenformin-like drugs.”
In addition, Alessi notes “there is still a lot of work to do to under-
stand LKB1’s interaction with STRAD and MO25, and how the combined
unit performs its role in phosphorylating AMPK. STRAD itself appears to
be a very interesting molecule in that its sequence suggests that it should
also be a protein kinase, but it is an inactive ‘pseudokinase’.suggestions that LKB1 is controlling
cell polarity,” comments Pawson,
adding, “one would imagine that this
is through a different target - or is
LKB1 only functioning as an AMPK
kinase?” The degree of interest in this
area is evident from the fact that while
the Alessi and Hardie labs were carry-
ing out these additional experiments,
the groups of Marian Carlson and
David Carling jointly published data
pointing to the possibility that LKB1
might be the upstream kinase for
AMPK [3].
Drugs, diabetes and cancer
At the same time as working on verify-
ing LKB1 as the AMPK activating
kinase, Hardie and Alessi had been
testing their cells with two different
drugs that stimulate AMPK in wild-type
cells. One was phenformin, a close
cousin of metformin, the active ingredi-
ent of the world’s best-selling product
for combating type II diabetes (Glu-
cophage). In muscle, phenformin and
metformin activate AMPK and thus
mimic the effect of exercise, stimulating
the cells to increase the uptake and
metabolism of glucose and fatty acids.
In cells that have no LKB1 - either HeLa
cells or those from LKB1 knockout
mouse embryos - phenformin could
not activate AMPK, but in modified
HeLa cells containing the recombinant
LKB1 gene, or in wild-type mouse
fibroblasts, the drug worked.
Alessi and Hardie found a similar
situation with AICA riboside, another
AMPK-activating drug that laboratory
tests had shown could be used as a
treatment for diabetes in animals. The
molecule is converted inside the cell
into AICA riboside monophosphate
(ZMP), an analog of AMP. A few years
earlier, Hardie had shown that the
levels of AMP within a cell are critical
indicators of cell stress, and are used
by the cell as the signal that switches
on AMPK to regulate metabolism.
They now discovered that treatment of
cells with AICA riboside also had no
effect in the absence of LKB1.
With the number of people who
have type II diabetes increasing dra-
matically around the world (it is esti-
mated that there will be 200 million
by the end of this decade), many phar-
maceutical companies are looking for
new ways of combating the disease.
The patent has just lapsed on met-
formin, and in any case it is not a very
potent AMPK activator, so there is a
keen interest in developing a second-
generation drug that will directly target
AMPK. But it will not be easy. Most
drugs are inhibitors, but what is
required here is an activator. Now,
however, there is a second option,
because it may be possible to achieve
the same results by targeting LKB1.
As well as having an impact on dia-
betes, the work has an obvious poten-
tial spin-off for patients with
Peutz-Jeghers syndrome. “Pharmaceu-
tical companies have been working
with AMPK for years, so they must
have numerous compounds on their
shelves that they could screen for effi-
cacy against the disease,” says Wood-
gett. It may also be that studying LKB1
and AMPK holds the potential for
yielding a new class of therapy for
treatment of other more common
types of cancer. One thing is certain -
the two proteins are now hot property.
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